Ironwood to present data from Landmark survey on SBS

Ironwood (IRWD) Pharmaceuticals announced that the company will present data from its Landmark survey during the 2026 Digestive Disease Week, DDW, meeting being held from May 2-5 in Chicago, IL. The data will spotlight healthcare professional insights on the burden of total parenteral nutrition, TPN, for patients with short bowel syndrome, SBS, as well as preferred attributes for potential new therapies that reduce TPN dependence. “Short bowel syndrome remains a complex and underserved condition where patients and clinicians face significant challenges, particularly for those who rely on parenteral support, which is often life-sustaining but can be associated with substantial treatment burden,” said Michael Shetzline, M.D., Ph.D., chief medical officer, senior vice president and head of research and drug development at Ironwood Pharmaceuticals. “By bringing forward real-world healthcare professional perspectives, we aim to deepen understanding of current management and the factors that shape SBS-IF care in everyday practice and help inform future therapeutic approaches.”